 <h1>Acthar Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>corticotropin</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about corticotropin. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Acthar.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to corticotropin: parenteral solution for injection</i></p><p>Side effects include:</p><p>Associated with long-term therapy: Bone loss, cataracts, indigestion, muscle weakness, back pain, bruising, acne, hyperpigmentation, menstrual irregularities, oral candidiasis.    (See Warnings/Precautions under Cautions.)</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to corticotropin: injectable powder for injection, injectable solution</i></p><h3>General</h3><p>The more commonly reported adverse effects have included fluid retention, changes in glycemic control, increased appetite and weight gain; for children less than 2 years, increased risk of infections, hypertension, irritability, Cushingoid symptoms, cardiac hypertrophy, and weight gain have been reported.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>The incidence of cardiac hypertrophy in patients less than 2 years treated for infantile spasm was 3% for patients receiving 75 units/m2 twice a day and 0% for those receiving 150 units/m2/day based on retrospective chart reviews and clinical trials.  For hypertension, the incidence of was 11% for patients receiving 75 units/m2 twice a day and 19% for those receiving 150 units/m2/day.</p><p>Very Common (10% or more): Hypertension</p><p><b>Common</b> (1% to 10%): Cardiac hypertrophy</p><p><b>Frequency not reported</b>: Fluid retention</p><p><b>Postmarketing reports</b>: Necrotizing angitis (adults only), congestive heart failure</p><h3>Nervous system</h3><p>In the treatment of infantile spasms, other types of seizures/convulsions may occur because some patients progress to other forms of seizures such as Lennox-Gastaut syndrome and because spasms may be masking other seizures.  The incidence of seizure was 12% for patients receiving 75 units/m2 twice a day and 3% for those receiving 150 units/m2/day based on retrospective chart reviews and clinical trials.</p><p>Very Common (10% to more): Convulsions</p><p><b>Postmarketing reports</b>: Headache (adults only), subdural hematoma, intracranial hemorrhage (adults only), reversible brain shrinkage (secondary to hypertension; infants only)</p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Irritability</p><p><b>Frequency not reported</b>: Behavioral and mood changes</p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Increased appetite, decreased appetite, weight gain</p><p><b>Frequency not reported</b>: Alteration in glucose tolerance</p><p><b>Postmarketing reports</b>: Hypokalemic alkalosis (infants only), decreased carbohydrate tolerance (infants only)</p><h3>Dermatologic</h3><p>The incidence of acne and rash in patients less than 2 years treated for infantile spasm was 0% for patients receiving 75 units/m2 twice a day and 12% and 8%, respectively for those receiving 150 units/m2/day based on retrospective chart reviews and clinical trials.</p><p><b>Very common</b> (10% or more): Acne</p><p><b>Common</b> (1% to 10%): Rash</p><p><b>Postmarketing reports</b>: Skin thinning (adults only), facial erythema, increased sweating (adults only), hirsutism</p><h3>Local</h3><p><b>Postmarketing reports</b>: Injection site reactions</p><h3>Musculoskeletal</h3><p><b>Postmarketing reports</b>: Muscle weakness and vertebral compression fractures (infants only)</p><h3>Endocrine</h3><p>The incidence of Cushingoid in patients less than 2 years treated for infantile spasm was 3% for patients receiving 75 units/m2 twice a day and 22% for those receiving 150 units/m2/day based on retrospective chart reviews and clinical trials.</p><p><b>Common</b> (1% to 10%): Cushingoid</p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea</p><p><b>Common</b> (1% to 10%): Constipation, diarrhea, vomiting</p><p><b>Postmarketing reports</b>: Pancreatitis (adults only), abdominal distention, ulcerative esophagitis</p><h3>Hypersensitivity</h3><p><b>Postmarketing reports</b>: Allergic responses presenting as dizziness, nausea, and shock (adults only)</p><h3>Other</h3><p>Very Common (10% or more): Infection</p><p><b>Common</b> (1% or 10%): Pyrexia, candidiasis, otitis media, vertigo (adults only)</p><h3>Respiratory</h3><p><b>Common</b> (1% or 10%): Nasal congestion, pneumonia, upper respiratory infections.</p><p id="ref_1">1. "Product Information. Acthar Gel, H.P. (corticotropin)." Questcor Pharmaceuticals Inc., Union City, CA. </p><h2>More about Acthar (corticotropin)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>12 Reviews</li>
<li>Drug class: corticotropin</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul><h3>Other Formulations</h3><ul class="more-resources-list more-resources-list-formulations">
<li>Acthar Gel, H.P.</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Allergies</li>
<li>Ankylosing Spondylitis</li>
<li>Chorioditis</li>
<li>Chorioretinitis</li>
<li data-more-config-id="list-data-resources-conditions">... +19 more</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>